CVX vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Chevron Corporation and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Chevron Corporation · Energy
$188.52
-23.1% upside to fair value
Grade D
VS
Johnson & Johnson · Healthcare
$238.46
-11.8% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
JNJ has more upside to fair value
(-11.8%).
JNJ trades at a lower forward P/E
(20.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CVX |
JNJ |
| Current Price |
$188.52 |
$238.46 |
| Fair Value Estimate |
$145.00 |
$210.28 |
| Upside to Fair Value |
-23.1%
|
-11.8%
|
| Market Cap |
$376.9B |
$574.7B |
| Forward P/E |
22.9x
|
20.2x
|
| EV / EBITDA |
7.8x
|
13.3x
|
| Price / Sales |
1.5x
|
6.2x
|
| Price / FCF |
17.0x
|
29.4x
|
| Revenue Growth YoY |
-4.6%
|
+6.1%
|
| Gross Margin |
30.4%
|
72.8%
|
| Operating Margin |
9.0%
|
27.2%
|
| Return on Equity |
6.6%
|
32.87%
|
| Dividend Yield |
4.52% |
2.18% |
| FCF Yield |
5.89%
|
3.4%
|
| Analyst Consensus |
Buy
|
Moderate Buy
|
Investment Thesis
Chevron Corporation is a leading integrated oil and gas major with global upstream and downstream operations, a fortress balance sheet, and a shareholder-friendly capital return program. Under CEO Mike Wirth, the company has prioritized disciplined capital allocation, returning over $27 billion to shareholders in 2024 alone through buybacks and dividends, while maintaining a 38-year streak of con…
Johnson & Johnson is a high-quality healthcare conglomerate focused exclusively on Innovative Medicine and MedTech following the Kenvue spin-off. The company delivered $94.2B in FY2025 revenue with 6% operational growth, generated $19.7B in free cash flow, and guided for $99.5-100.5B in 2026 operational sales (above consensus). However, at $238 the stock trades at a P/S of 6.15x, well above the 5…
Accumulation Zones
| Metric |
CVX |
JNJ |
| Zone Low |
$108.75 |
$157.71 |
| Zone High |
$123.25 |
$178.74 |
| In Buy Zone? |
No
|
No
|